Trial · NCT06962930
An Online Physical Activity Coaching Intervention for People With PD in Qatar
NCT06962930, Not applicable, Recruiting, Qatar University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. An Online Physical Activity Coaching Intervention for People With PD in Qatar. Trials, record NCT06962930. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06962930
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Online Physical Activity Coaching Intervention for People With PD in Qatar
- NCT number
- NCT06962930
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Qatar University
- Conditions
- Parkinson Disease
- Interventions
- 8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions
- First posted
- 2025-05-08
- Last updated
- 2025-09-29
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Physical activity | 7 days | 7 day physical activity (i.e., moderate/vigorous activity minutes) using a waist-worn activity monitor (Actigraph) |
| Secondary | The Physical Activity Scale for Individuals with Physical Disabilities (PASIPD) | less than 5 minutes | Modified disability version of the 10 item Physical Activity Scale for the Elderly (PASE), Captures information about leisure, household, and work-related physical activity over the preceding 7 days, Developed targeting individuals with visual/auditory and locomotor/SCI disabilities. |
| Secondary | International Physical Activity Questionnaire (IPAQ) short form | 5 minutes | This measure will ask about the time spent being physically active in the last 7 days. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity. |
| Secondary | Six-Minute Walk Test (6MWT) | 10 minutes | The 6-Minute Walk test is a measure of endurance. The Subjects will be asked to walk around the perimeter of a set circuit for a total of 6 minutes. |
| Secondary | The Short Self-Efficacy for Exercise Scale (SSEE) | 5 minutes | is a self-report questionnaire composed of nine items for the assessment of self-efficacy for exercise |
| Secondary | 8-item Parkinson's Disease Questionnaire (PDQ-8) | 5-10 minutes | The 8-item version of the Parkinson's Disease Questionnaire (PDQ-8) is a shortened version of the 39-item Parkinson's Disease Questionnaire (PDQ-39). It was developed to reduce the respondent burden and increase convenience for use among persons with Parkinson's Disease in clinical settings. PDQ-39 comprises 39 questions from 8 dimensions which include mobility, activities of daily of living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.PDQ-8 was constructed by taking one question from each domain of PDQ-39 |
| Secondary | MDS-UPDRS-II Motor Experiences of Daily Living | 10 minutes | The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease. The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease. . It is consisting of 4 parts one of them is MDS-UPDRS-II Motor Experiences of Daily Living it's about motor aspects of experiences of daily living (M-EDL). |
| Secondary | MDS-UPDRS-III Motor Examination | 15 minutes | The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease. The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease. It is consists of 4 parts one of them is MDS-UPDRS-III Motor Examination its assesses the motor signs of PD |
| Secondary | Levodopa Equivalent Daily Doses (LEDD) | 5 minutes | The Levodopa Equivalent Daily Dose (LEDD) is a useful calculation for comparing the doses of different Parkinson's disease medications to their equivalent amount of Levodopa. This helps clinicians to evaluate the overall dopaminergic load a patient is receiving. Various Parkinson's medications, such as Levodopa, Dopamine Agonists, and MAO-B inhibitors, can be converted into an equivalent dose of Levodopa using standard conversion factors. |
| Secondary | Mini Balance Evaluation Systems Test (Mini-BEST) | 10-15 minutes | balance assessment tool is a shortened version of the Balance Evaluation Systems Test (BESTest) consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest. It aims to target and identify 6 different balance control systems so that specific rehabilitation approaches can be designed for different balance deficits. The BESTest was shortened based on factor analysis to include dynamic balance only and to improve clinical utilization. |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06962930
GET https://conductscience.org/api/trials/v1/NCT06962930/registered?page=2